## CLAIMS

1. A dosage form comprising (*S*)-bupropion which is at least 95% enantiomerically pure.

2. The dosage form of claim 1, which contains about 50 mg to about 100 mg of (*S*)-bupropion.

3. The dosage form of claim 1, which contains about 100 mg to about 200 mg of (*S*)-bupropion.

4. The dosage form of claim 1, 2, or 3, wherein the dosage form contains less than 0.1% of any other active pharmaceutical agent.

5. The dosage form of claim 1, 2, 3, or 4, wherein the dosage form achieves a $C_{max}$ of (*S*)-bupropion that is at least about 60 ng/mL when administered to a human being in need thereof.

6. The dosage form of claim 1, 2, 3, 4, or 5, wherein the dosage form achieves a $C_{max}$ of (*R,R*)-hydroxybupropion that is at least about 500 ng/mL when administered to a human being in need thereof.

7. The dosage form of claim 1, 2, 3, 4, 5, or 6, wherein the dosage form achieves an $AUC_{0\text{-}12}$ of (*S*)-bupropion that is at least about 400 ng·hr/mL when administered to a human being in need thereof.

8. The dosage form of claim 1, 2, 3, 4, 5, 6, or 7, wherein the dosage form achieves an $AUC_{0\text{-}12}$ of (*R,R*)-hydroxybupropion that is at least about 7000 ng·hr/mL when administered to a human being in need thereof.

9. The dosage form of claim 1, 2, 3, 4, 5, 6, 7, or 8, wherein the dosage form provides sustained release of the (*S*)-bupropion.

10. The dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, or 9, wherein the dosage form is well tolerated when administered to a human being.

11. Use of the dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 for the manufacture of a medicament for treating a condition that is treatable with racemic bupropion in a human being in need thereof.

12. The use of claim 11, wherein the human being having the condition that is treatable by orally administering a reference dosage form containing a first amount of racemic bupropion at a first dosing frequency; and

orally administering a dosage form containing a second amount of (*S*)-bupropion that is at least 95% enantiomerically pure at the first dosing frequency to achieve the same therapeutic effect that would be achieved by administering the reference dosage form at the first dosing frequency;

wherein the first dosing frequency is once daily or twice daily; and

wherein the second amount is about 40% to about 60% of the first amount.

13. Use of the dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 for the manufacture of a medicament for treating a central nervous system (CNS) disorder.

14. The use of claim 13, wherein the CNS disorder comprises depression.

15. The use of claim 13, wherein the CNS disorder comprises treatment-resistant depression.

16. The use of claim 13, wherein the CNS disorder comprises an addictive disorder.

17. The use of claim 13, wherein the CNS disorder comprises a nicotine addiction.

18. The use of claim 13, wherein the CNS disorder comprises an alcohol addiction.

19. The use of claim 13, wherein the CNS disorder comprises attention deficit/hyperactivity disorder.

20. Use of the dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 for the manufacture of a medicament for relieving pain in a human being in need thereof.